News headlines about Heska (NASDAQ:HSKA) have trended positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Heska earned a coverage optimism score of 0.27 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 45.2591761011112 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
A number of brokerages have recently commented on HSKA. B. Riley reiterated a “hold” rating and issued a $96.50 target price on shares of Heska in a research report on Friday, October 27th. BidaskClub cut shares of Heska from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. Raymond James Financial reiterated a “buy” rating on shares of Heska in a research report on Monday, December 4th. ValuEngine cut shares of Heska from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, Sidoti upgraded shares of Heska from a “neutral” rating to a “buy” rating and set a $94.00 target price for the company in a research report on Monday, February 5th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $110.08.
Shares of Heska (NASDAQ:HSKA) traded up $0.49 during midday trading on Friday, hitting $60.60. 188,400 shares of the stock were exchanged, compared to its average volume of 91,536. Heska has a 1-year low of $56.59 and a 1-year high of $115.00. The firm has a market capitalization of $435.42, a PE ratio of 31.73, a price-to-earnings-growth ratio of 1.56 and a beta of 0.67.
In related news, insider Michael J. Mcginley sold 7,826 shares of the company’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total value of $681,957.64. Following the completion of the sale, the insider now owns 106,771 shares of the company’s stock, valued at $9,304,024.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 14.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Positive News Coverage Somewhat Unlikely to Affect Heska (HSKA) Stock Price” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/16/positive-news-coverage-somewhat-unlikely-to-affect-heska-hska-stock-price.html.
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.